Eton pharmaceuticals, inc. (ETON)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17
Revenues
Total revenues

99

459

0

0

500

-

-

-

-

-

Cost of product sales

102

-

-

-

-

-

-

-

-

-

Gross (loss) profit

-3

-

-

-

500

-

-

-

-

-

Operating expenses:
Research and development

6,268

233

3,418

1,439

6,465

1,102

1,544

1,707

1,274

1,564

General and administrative

2,610

2,429

1,624

1,910

1,589

1,184

830

990

1,690

1,206

Total operating expenses

8,878

2,662

5,042

3,349

8,054

2,286

2,374

2,697

2,964

2,770

Loss from operations

-8,881

-2,656

-5,042

-3,349

-7,554

-2,286

-2,374

-2,697

-2,964

-2,770

Other (expense) income:
Interest and other (expense) income, net

-168

-

-

-

144

-

-

-

-

-

Interest and other income, net

-

-

77

100

-

82

25

28

29

9

Change in fair value of warrant liability

-

-

-

-

-

1,526

561

413

83

41

Loss before income tax expense

-9,049

-2,696

-4,965

-3,249

-7,410

-3,730

-2,910

-3,082

-3,018

-2,802

Income tax expense

-

-

-

-

-

-

-

-

-

0

Net loss

-9,049

-2,696

-4,965

-3,249

-7,410

-3,730

-2,910

-3,082

-3,018

-2,802

Accrued dividends on redeemable convertible preferred stock

-

-

-

-

-

148

300

304

296

303

Deemed dividends for accretion of redeemable convertible preferred stock issuance costs

-

-

-

-

-

437

429

418

410

388

Net loss attributable to common stockholders

-

-

-4,965

-3,249

-

-26,062

-3,639

-3,804

-3,724

-3,493

Net loss per share, basic and diluted

-0.50

-0.15

-0.28

-0.18

-0.42

-3.31

-0.65

-0.79

-1.05

-1.00

Weighted average number of common shares outstanding, basic and diluted

18,143

17,931

17,878

17,733

17,502

11,720

5,615

4,786

3,551

3,500

Product Sales [Member]
Total revenues

99

-

-

-

-

-

-

-

-

-

Licensing Revenue [Member]
Total revenues

-

-

-

-

500

-

-

-

-

-